Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/anagrelide.aspx Anagrelide (Agrylin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-09-26: Initial approval for the treatment of [[essential thrombocythemia]]. | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Agrylin, Xagrid | *'''Brand names:''' Agrylin, Xagrid | ||
| Line 31: | Line 33: | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
| + | [[Category:EMA approved in 2004]] | ||
| + | [[Category:PMDA approved in 2014]] | ||
Latest revision as of 23:52, 2 September 2023
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO four times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]
History of changes in PMDA indication
- 2014-09-26: Initial approval for the treatment of essential thrombocythemia.
Also known as
- Brand names: Agrylin, Xagrid